Personalizing Busulfan Therapy for Children Undergoing Hematopoietic Stem Cell Transplantation

Anuj K Tyagi; Patricia Huezo-Diaz; Marc Ansari

Disclosures

Personalized Medicine. 2014;11(5):463-466. 

In This Article

Conclusion

Tailoring or personalizing first dose of BU with due consideration of demographics and genotypes of GSTA1 and M1 genes could possibly help in achieving better clinical outcomes in pediatric HSCT. A model for the dosage adjustment with the inclusion of genetic and nongenetic factors shall be developed and evaluated in prospective validation cohorts to establish its utility in routine pediatric HSCT centers.

processing....